Skip to main content

Table 5 Matrix effect evaluation of SAX and 5-OH SAX (n = 3, sources = 6)

From: Pharmacokinetic/Pharmacodynamic modelling of Saxagliptin and its active metabolite, 5-hydroxy Saxagliptin in rats with Type 2 Diabetes Mellitus

Analytes

Norminal concentration (ng/mL)

Analyte matrix effect (%)

IS normalization analyte matrix effect (%)

Mean

SD

RSD

Mean

SD

RSD

SAX

15

92.36

2.96

3.21

109.39

5.56

5.08

2000

84.26

1.50

1.78

100.42

4.33

4.31

5-OH SAX

3

86.61

3.32

3.83

104.00

5.34

5.13

400

85.01

3.60

4.23

102.12

4.13

4.04